Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

s release related July 16, 2009 for more information about the Phase I clinical trial.
  • In a double-blind test, for the purpose of conducting the clinical trial in a completely objective manner, the physicians performing the trial as well as the patients participating in the trial do not know if the substance administered to each individual is the drug being tested or the placebo.
  • The placebo is a substance that does not include the drug being tested (RK-023 in this case).
  • About R-Tech Ueno, Ltd.

    R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. The company's main product Rescula(R) eyedrop 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R). Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company. Rescula(R) eyedrop 0.12% that causes less topical and systemic adverse reactions demonstrates steady ocular pressure-decreasing action by twice-a-day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow-increasing mechanism.

        Stock Code: No.4573, Osaka Securities Exchange; Hercules
        Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
        Representative Director & President: Yukihiko Mashima
    
    
        Contact:
        Koji Nakamura,
        Business Management Department
        R-Tech Ueno, Ltd.
        Tel: +81-3-3596-8011
        e-mail: koji.nakamura@rtueno.co.jp
        URL: '/>"/>
    SOURCE R-Tech Ueno, Ltd.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
    2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
    3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
    4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
    5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
    6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
    7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
    8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
    9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
    10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
    11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
    (Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
    (Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
    Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
    ... , ATLANTA, Nov. 30 Amoena USA Corporation, ... the 4th Annual Breast Cancer Survivors Cruise. In 2010, for ... who helped them through their recovery by awarding a cabin ... , As part of the contest, Amoena wants to hear ...
    ... , ... the world,s leading research and advisory firms focusing on pharmaceutical ... market in Russia will grow nine percent annually over the ... This growth will be driven mainly by increased government spending ...
    Cached Medicine Technology:Amoena and Young Survival Coalition Celebrate Breast Cancer Survivors With Contest and Cruise 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3
    (Date:7/12/2014)... (PRWEB) July 12, 2014 Demand Response ... with considerable benefits in reducing the imbalance between energy ... grid appliances have been rolled out (due to increasing ... Infrastructure (AMI). This helps in controlling residential appliances and ... growing in the North American region, and with government ...
    (Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
    (Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
    (Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
    (Date:7/12/2014)... 2014 With prom shopping reaching its ... retailer, is ready to showcase its new and trendy ... of evening dresses in its online shop. Additionally, it ... for these elegant gowns. According to the company’s sales ... July 26, 2014. , He says, “Now, worldwide ...
    Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
    ... Va. (April 13, 2009) While the number of ... registry still only includes 38 percent of licensed drivers, according ... year. Yet, according to a new survey of Americans, ... even if their family disagrees. , "The number of ...
    ... Rx, Inc., the,pioneering force in measuring the impact of ... physicians, announces that Mark,Degatano has joined the company as ... a newly-created position that expands and,strengthens Impact Rx,s business ... his new role Degatano will lead programs at the ...
    ... ... April 13, 2009 -- Accept an illicit injection and the result ... Coalition for Injectable Safety. The recent death of a Bronx, NY ... her thighs and buttocks is an unfortunate and repeating pattern of incidents ...
    ... FARMINGDALE, N.Y., April 13 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has entered into a new, three year, ... Avanco Sistemas Medicos, based in Barcarena, Portugal, for the ...
    ... wide today as it was in the early ,90s, study ... with lung cancer are less likely than white patients to ... Disparities in lung cancer treatments were as large in 2002 ... there have been efforts to decrease those inequalities in treatment, ...
    ... As all eyes turn to the health reform debate in ... of California - will urge that "everything be on the ... D.C. Mr. Bodaken will participate in a keynote panel kicking ... that begins with an address by Dora Hughes, counselor to the ...
    Cached Medicine News:Health News:While majority of Americans express interest in organ and tissue donation, few register 2Health News:Impact Rx, Inc. Names Mark Degatano as Vice President, Business Development, Key Client Initiatives 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 3Health News:Consumer Alert: Illegal Silicone Injections Result in Death 4Health News:Misonix Announces New Distribution Agreement for Portugal 2Health News:Misonix Announces New Distribution Agreement for Portugal 3Health News:Blacks Less Likely to Get Optimal Lung Cancer Treatment 2Health News:Blue Shield of California CEO to Speak at World Health Care Congress in Washington D.C. 2
    ... is a low profile implantable bipolar ... stimulation of either the atrium (preformed ... model). All ZY leads are supplied ... used to extend/retract the fixation helix ...
    ... are small profile endocardial permanent pacing leads ... lead body size of only 4.8 F ... F, the Physique lead is the smallest ... in both straight and pre-formed J configurations, ...
    Used with Temporary Myocardial Heartwires....
    Used with permanent pacing leads....
    Medicine Products: